Corcept Therapeutics Inc., which plans to submit data to the FDA by the end of the month on a possible treatment for the hormonal disorder Cushing's Syndrome, lost $7.1 million in the fourth quarter and $26 million in 2010.
The Menlo Park company (NASDAQ: CORT) lost $5.2 million a year earlier in the fourth quarter. It reported no revenue in either quarter.
No comments:
Post a Comment